Home » Stocks » Kadmon Holdings

Kadmon Holdings, Inc. (KDMN)

Stock Price: $4.13 USD -0.04 (-0.96%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 706.80M
Revenue (ttm) 12.16M
Net Income (ttm) -130.57M
Shares Out 171.14M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $4.13
Previous Close $4.17
Change ($) -0.04
Change (%) -0.96%
Day's Open 4.12
Day's Range 4.05 - 4.14
Day's Volume 944,689
52-Week Range 2.04 - 5.50

More Stats

Market Cap 706.80M
Enterprise Value 541.43M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 171.14M
Float 111.63M
EPS (basic) -0.93
EPS (diluted) -0.89
FCF / Share -0.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 26.18M
Short Ratio 11.22
Short % of Float 15.32%
Beta 1.29
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 58.11
PB Ratio 7.59
Revenue 12.16M
Operating Income -84.55M
Net Income -130.57M
Free Cash Flow -73.93M
Net Cash 165.36M
Net Cash / Share 0.97
Gross Margin 31.29%
Operating Margin -695.08%
Profit Margin -1,123.00%
FCF Margin -607.77%
ROA -24.62%
ROE -85.81%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$12.80*
(209.93% upside)
Low
8.00
Current: $4.13
High
25.00
Target: 12.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue5.101.4012.2626.0635.7295.02
Revenue Growth264.97%-88.62%-52.93%-27.06%-62.41%-
Gross Profit3.810.719.2822.1929.7183.98
Operating Income-89.08-85.90-68.56-120-140-38.29
Net Income-61.37-54.25-79.77-209-147-64.36
Shares Outstanding13297.6157.4123.678.137.79
Earnings Per Share-0.48-0.58-1.42-9.74-18.10-8.27
Operating Cash Flow-80.07-71.23-64.10-52.95-60.98-8.49
Capital Expenditures-0.52-0.86-0.48-0.54-0.16-2.06
Free Cash Flow-80.58-72.09-64.58-53.49-61.14-10.56
Cash & Equivalents18496.8669.6338.2123.6123.02
Total Debt19.7627.4833.7130.58215165
Net Cash / Debt16469.3835.937.63-191-142
Assets21514583.5562.5684.14123
Liabilities49.0656.2581.7987.75296241
Book Value16688.411.76-25.19-271-155
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kadmon Holdings, Inc.
Country United States
Employees 115
CEO Harlan W. Waksal

Stock Information

Ticker Symbol KDMN
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSE: KDMN
IPO Date July 27, 2016

Description

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.